ReachMD

Dr. Paul G. Richardson is Clinical Program Leader and Director of Clinical Research at the Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute and a Professor of Medicine at Harvard Medical School.

Dr. Richardson’s primary research interest is in novel therapies, and he has been a leader in the clinical development of bortezomib, lenalidomide, and pomalidomide. He pioneered the development of lenalidomide, bortezomib, and dexamethasone for myeloma treatment. He is Principal Investigator for several clinical trials relating to other areas of myeloma treatment, including the use of combination therapies in earlier disease designed to target resistance and reduce toxicity.

Dr. Richardson serves on the editorial boards of the Journal of Clinical Oncology, the Journal of Oncology, The Oncologist, Clinical Cancer Research, and the British Journal of Hematology. He serves on the steering committee and project review committee for the Multiple Myeloma Research Consortium, Clinical Trials Core. He is Chairperson of the newly formed Multiple Myeloma Committee for the Alliance for Clinical Trials in Oncology (the former CALGB). Dr. Richardson has written more than 280 original articles and more than 180 reviews, chapters, and editorials in leading peer-reviewed journals including The New England Journal of Medicine, Blood, Journal of Clinical Oncology, Leukemia, Clinical Cancer Research, and British Journal of Haematology.

Dr. Richardson earned an MD from the Medical College of St. Bartholomew’s Hospital in London, where he completed an internship in medicine and surgery. He completed a residency in medicine at Newcastle University School of Medicine. He was appointed chief resident in medical oncology at the Royal Marsden Hospital in London and Surrey and completed additional residency training at the Beth Israel Hospital in Boston. He completed fellowships in hematology/oncology and medical oncology at Tufts University School of Medicine in Boston; Baystate Medical Center in Springfield, Massachusetts; and Harvard Medical School, Dana-Farber Cancer Institute in Boston.